Eloralintide vs Tirzepatide | GLP-1R/GCGR vs Dual GLP-1/GIP | QSC
Eloralintide vs Tirzepatide
GLP-1R/GCGR Dual Agonist vs Dual GLP-1/GIP — Mechanism, Data & Research Application Comparison | QSC
Factor
Eloralintide
Tirzepatide
Class
Dual GLP-1R/GCGR Agonist
Dual GLP-1/GIP
Mechanism
GLP-1R + GCGR co-agonism
GLP-1R+GIPR dual agonist
Best Trial Result
~10–11% wt loss · ~40–50% liver fat ↓
−20.9% (SURMOUNT-1, 72w)
NASH / Liver Data
✓ Phase 2 — direct GCGR/CPT1A
SYNERGY-NASH 62.4%
GCGR Component
✓ Direct hepatic fat oxidation
✗
At QSC
✓ In stock — first mover
✓ In stock
Research Analysis: Different second receptors: tirzepatide = GIPR (adipose lipolysis, thermogenesis, hypothalamic GLP-1R sensitisation). Eloralintide = GCGR (hepatic CPT1A fat oxidation, UCP1 thermogenesis). Tirzepatide delivers higher weight loss (−20.9% vs ~10–11%) — GIPR adds powerful adipose effects. Eloralintide delivers superior direct liver fat reduction per unit of weight loss — GCGR drives hepatic fat oxidation directly. For NASH hepatic mechanism research with GCGR isolation: eloralintide. For maximal weight loss efficacy among approved compounds: tirzepatide.
What is the difference between eloralintide and Tirzepatide?
Eloralintide is a dual GLP-1R/GCGR co-agonist; Tirzepatide is a Dual GLP-1/GIP. The key mechanistic difference is the presence or absence of GCGR: eloralintide’s GCGR agonism drives direct hepatic CPT1A-mediated fat oxidation — independent of body weight loss. Different second receptors: tirzepatide = GIPR (adipose lipolysis, thermogenesis, hypothalamic GLP-1R sensitisation). Eloralintide = GCGR (hepatic CPT1A fat oxidation, UCP1 thermogenesis). Tirzepatide delivers higher weight loss (−20.9% vs ~10–11%) —
Which is better for NASH research: eloralintide or Tirzepatide?
For research specifically targeting direct hepatic fat oxidation via GCGR/CPT1A, eloralintide is the dedicated tool — Phase 2 data shows ~40–50% liver fat reduction, disproportionate to ~10–11% weight loss. Tirzepatide reduces liver fat secondarily via weight loss without a direct GCGR hepatic mechanism.
Are both eloralintide and Tirzepatide available at QSC?
Yes — both eloralintide and Tirzepatide are available at QSC (qscpeptide.com) at ≥99% HPLC purity with Janoshik independent COA verification. US Domestic Warehouse, 2–4 business day delivery. Researchers can source both compounds from one verified supplier for comparative protocols.
Research Use Only: Eloralintide is sold by QSC strictly for in vitro laboratory research purposes only. Not for human or veterinary use. Not FDA approved for clinical use.
